Patents by Inventor Fathy Majadly
Fathy Majadly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9096653Abstract: Disclosed are immunogenic conjugates which elicit an immune response to Plasmodium proteins. In particular examples, the Plasmodium proteins include sexual stage surface proteins, circumsporozoite protein (CSP), or immunogenic portions of CSP. Also provided herein are immunogenic compositions including one or more of the disclosed immunogenic conjugates and a pharmaceutically acceptable carrier. Further provided is a method of eliciting an immune response to Plasmodium in a subject, comprising administering to the subject an immunogenic composition disclosed herein.Type: GrantFiled: April 25, 2013Date of Patent: August 4, 2015Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, New York UniversityInventors: Rachel Schneerson, Joanna Kubler-Kielb, John B. Robbins, Fathy Majadly, Christopher P. Mocca, Jerry Keith, Zuzana Biesova, Louis Miller, Ruth Nussenzweig, Darrell T. Liu
-
Publication number: 20150050314Abstract: Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.Type: ApplicationFiled: October 29, 2014Publication date: February 19, 2015Applicant: The United States of America as represented by the Secretary, Department of Health and Human ServiceInventors: Rachel Schneerson, Joanna Kubler-Kielb, Yimin Wu, Louis Miller, Fathy Majadly, John B. Robbins
-
Patent number: 8900599Abstract: Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.Type: GrantFiled: January 25, 2013Date of Patent: December 2, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Rachel Schneerson, Joanna Kubler-Kielb, Yimin Wu, Louis Miller, Fathy Majadly, John B. Robbins
-
Patent number: 8481048Abstract: Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazine-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.Type: GrantFiled: October 20, 2009Date of Patent: July 9, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of HealthInventors: Rachel Schneerson, Joanna Kubler-Kielb, Fathy Majadly, Stephen H. Leppla, John B. Robbins, Darrell T. Liu, Joseph Shiloach
-
Patent number: 8444996Abstract: Disclosed are immunogenic conjugates which elicit an immune response to Plasmodium proteins. In particular examples, the Plasmodium proteins include sexual stage surface proteins, circumsporozoite protein (CSP), or immunogenic portions of CSP. Also provided herein are immunogenic compositions including one or more of the disclosed immunogenic conjugates and a pharmaceutically acceptable carrier. Further provided is a method of eliciting an immune response to Plasmodium in a subject, comprising administering to the subject an immunogenic composition disclosed herein.Type: GrantFiled: October 1, 2009Date of Patent: May 21, 2013Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, New York UniversityInventors: Rachel Schneerson, Joanna Kubler-Kielb, John B. Robbins, Fathy Majadly, Christopher P. Mocca, Jerry Keith, Zuzana Biesova, Louis Miller, Ruth Nussenzweig, Darrell T. Liu
-
Publication number: 20110182929Abstract: Disclosed are immunogenic conjugates which elicit an immune response to Plasmodium proteins. In particular examples, the Plasmodium proteins include sexual stage surface proteins, circumsporozoite protein (CSP), or immunogenic portions of CSP. Also provided herein are immunogenic compositions including one or more of the disclosed immunogenic conjugates and a pharmaceutically acceptable carrier. Further provided is a method of eliciting an immune response to Plasmodium in a subject, comprising administering to the subject an immunogenic composition disclosed herein.Type: ApplicationFiled: October 1, 2009Publication date: July 28, 2011Inventors: Rachel Schneerson, Joanna Kubler-Kielb, John B. Robbins, Fathy Majadly, Christopher P. Mocca, Jerry Keith, Zuzana Biesova, Louis Miller, Ruth Nussenzweig, Darrell T. Liu
-
Patent number: 7803386Abstract: Immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacilli are provided that include immunogenic conjugates of a poly-?-glutamic acid (?PGA) polypeptide of B. anthracis, or of another Bacillus that expresses a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against B. anthracis, or against another Bacillus, in mammalian hosts to which the conjugates are administered.Type: GrantFiled: June 4, 2004Date of Patent: September 28, 2010Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Rachel Schneerson, Stephen Leppla, John B. Robbins, Joseph Shiloach, Joanna Kubler-Kielb, Darrell Liu, Fathy Majadly
-
Publication number: 20100040644Abstract: Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazine-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.Type: ApplicationFiled: October 20, 2009Publication date: February 18, 2010Inventors: Rachel Schneerson, Joanna Kubler-Kielb, Fathy Majadly, Stephen H. Leppla, John B. Robbins, Darrell T. Liu, Joseph Shiloach
-
Patent number: 7625736Abstract: Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazino-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.Type: GrantFiled: December 6, 2004Date of Patent: December 1, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Rachel Schneerson, Joanna Kubler-Kielb, Fathy Majadly, Stephen H. Leppla, John B. Robbins, Darrell T. Liu, Joseph Shiloach
-
Publication number: 20060134143Abstract: Immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacilli are provided that include immunogenic conjugates of a poly-?-glutamic acid (?PGA) polypeptide of B. anthracis, or of another Bacillus that expresses a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against B. anthracis, or against another Bacillus, in mammalian hosts to which the conjugates are administered.Type: ApplicationFiled: June 4, 2004Publication date: June 22, 2006Inventors: Rachel Schneerson, Stephen Leppla, John Robbins, Joseph Shiloach, Joanna Kubler-Kielb, Darrell Liu, Fathy Majadly
-
Publication number: 20050271675Abstract: Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazino-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.Type: ApplicationFiled: December 6, 2004Publication date: December 8, 2005Inventors: Rachel Schneerson, Joanna Kubler-Kielb, Fathy Majadly, Stephen Leppla, John Robbins, Darrell Liu, Joseph Shiloah